Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 1 AL 15

Curcumin and curcumin-like molecules: from spice to drugs

Marchiani A, Rozzo C, Fadda A, Delogu G, Ruzza P.

Curr Med Chem. 2014;21(2):204-22. doi: 10.2174/092986732102131206115810.

Inhibition of amyloid-β aggregation in Alzheimer's disease

Wang Q, Yu X, Li L, Zheng J.

Curr Pharm Des. 2014;20(8):1223-43. doi: 10.2174/13816128113199990068.

Disruption of zinc neuromodulation by Aß oligomers: therapeutic implications

Vogler EC, Busciglio J.

Curr Pharm Des. 2014;20(15):2520-4. doi: 10.2174/13816128113199990510.

The effects of soluble Aβ oligomers on neurodegeneration in Alzheimer's disease

Brouillette J.

Curr Pharm Des. 2014;20(15):2506-19. doi: 10.2174/13816128113199990498.

In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches

Balducci C, Forloni G.

Curr Pharm Des. 2014;20(15):2491-505. doi: 10.2174/13816128113199990497.

Getting rid of intracellular Aβ- loss of cellular degradation leads to transfer between connected neurons

Agholme L, Hallbeck M.

Curr Pharm Des. 2014;20(15):2458-68. doi: 10.2174/13816128113199990501.

Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-β peptides, systemic ammonia and erythrocyte energy metabolism

Kosenko EA, Solomadin IN, Tikhonova LA, Reddy VP, Aliev G, Kaminsky YG.

CNS Neurol Disord Drug Targets. 2014 Feb;13(1):112-9. doi: 10.2174/18715273113126660130.

Current view from Alzheimer disease to type 2 diabetes mellitus

Rasool M, Malik A, Qazi AM, Sheikh IA, Manan A, Shaheen S, Qazi MH, Chaudhary AG, Abuzenadah AM, Asif M, Alqahtani MH, Iqbal Z, Shaik MM, Gan SH, Kamal MA.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):533-42. doi: 10.2174/18715273113126660167.

A nanotechnological approach to the management of Alzheimer disease and type 2 diabetes

Alam Q, ZubairAlam M, Karim S, Gan SH, Kamal MA, Jiman-Fatani A, Damanhouri GA, Abuzenadah AM, Chaudhary AG, Haque A.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):478-86. doi: 10.2174/18715273113126660159.

Bacteriophage--a common divergent therapeutic approach for Alzheimer's disease and type II diabetes mellitus

Sohrab SS, Karim S, Kamal MA, Abuzenadah AM, Chaudhary AG, Al-Qahtani MH, Mirza Z.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):491-500. doi: 10.2174/18715273113126660158.

Diabetes of the brain: computational approaches and interventional strategies

Narasimhan K, Govindasamy M, Gauthaman K, Kamal MA, Abuzenadeh AM, Al-Qahtani M, Kanagasabai R.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):408-17. doi: 10.2174/18715273113126660156.

Establishing genomic/transcriptomic links between Alzheimer's disease and type 2 diabetes mellitus by meta-analysis approach

Mirza Z, Kamal MA, Buzenadah AM, Al-Qahtani MH, Karim S.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):501-16. doi: 10.2174/18715273113126660154.

How do periodontal infections affect the onset and progression of Alzheimer's disease?

Shaik MM, Ahmad S, Gan SH, Abuzenadah AM, Ahmad E, Tabrez S, Ahmed F, Kamal MA.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):460-6. doi: 10.2174/18715273113126660152.

Role of gut microbiota in obesity, type 2 diabetes and Alzheimer's disease

Naseer MI, Bibi F, Alqahtani MH, Chaudhary AG, Azhar EI, Kamal MA, Yasir M.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):305-11. doi: 10.2174/18715273113126660147.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias